Checkpoint Therapeutics(CKPT) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 Waltham, MA – November 12, 2024 – Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2024, and recent corporate updates. "With the Prescription D ...